Achaogen, Inc. Company Profile
Achaogen is a clinical-stage biopharmaceutical company focused on the discovery and development of antibiotics for the treatment of serious infections caused by multi-drug resistant, Gram-negative bacteria. The companyâs pipeline includes ACHN-490, an aminoglycoside currently being evaluated in a Phase 2 clinical study for the treatment of complicated urinary tract infection (cUTI) and acute pyelonephritis, and late-stage preclinical programs with demonstrated in vivo efficacy against Gram-negative pathogens of concern including P. aeruginosa and A. baumannii. Resistance to available antibacterial therapies continues to rise at an alarming rate and Achaogen is applying its anticipatory science to meet this evolving need, developing drugs today intended to combat tomorrowâs resistant pathogens. Achaogen has established specialized capabilities to pursue the discovery and development of new antibiotics, and has funded its growth with a blend of private investments and non-dilutive funding from partnerships with the NIH, the United States Department of Defense, and others. For more information, please visit the companyâs website at www.achaogen.com.
News Articles
[Achaogen] brings in $30.7mm through its Series D venture round
[Achaogen Inc.] (antibiotics) has raised $30.7mm through what is believed to be its Series D venture round. There were 15 undisclosed investors.
Achaogen awarded $60 million contract option by BARDA for clinical development of Plazomicin
Achaogen, Inc has been awarded a $60 million contract option from the Biomedical Advanced Research and Development Authority (BARDA) supporting the conduct of a global Phase 3 superiority study that w...
Achaogen, U.S. Department of Health and Human Services infectious news
Achaogen Awarded $60M Contract Option by BARDA for the Clinical Development of Plazomicin
Achaogen, Inc. today announced the award of a $60M contract option from the Biomedical Advanced Research and Development Authority (BARDA). The option supports the conduct of a gl...
Drugs and Medications
None
PubMed Articles
Synthesis and Spectrum of the Neoglycoside ACHN-490.
ACHN-490 is a neoglycoside, or next-generation aminoglycoside (AG), that has been identified as a potentially useful agent to combat drug-resistant bacteria emerging in hospitals and health care facil...
Hybrid Aminoglycoside Antibiotics via Tsuji Palladium-Catalyzed Allylic Deoxygenation.
Biosynthetically inspired manipulation of the antibiotic paromomycin led, in six high-yielding steps, to a ring A harboring an α,β-unsaturated 6'-aldehyde and an allylic 3'-methylcarbonate group. Ts...
New aminoglycoside antibiotics.
Importance of the field: Nosocomial infections caused by multi-drug resistant (MDR) Gram-negative bacteria are on the increase, often with few or no therapeutic options for treatment. Historically, a...
Clinical Trials
None
Companies
Achaogen is a clinical-stage biopharmaceutical company focused on the discovery and development of antibiotics for the treatment of serious infections caused by multi-drug resista...
Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat multi-drug resistant bacterial infections.Â...
More Information about "Achaogen, Inc." on BioPortfolio
We have published hundreds of Achaogen, Inc. news stories on BioPortfolio along with dozens of Achaogen, Inc. Clinical Trials and PubMed Articles about Achaogen, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Achaogen, Inc. Companies in our database. You can also find out about relevant Achaogen, Inc. Drugs and Medications on this site too.
